Several analysts have recently updated their ratings and price targets for GlaxoSmithKline (LON: GSK):

  • 4/13/2018 – GlaxoSmithKline was given a new GBX 1,600 ($22.91) price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 4/12/2018 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Kepler Capital Markets.
  • 4/5/2018 – GlaxoSmithKline was given a new GBX 1,600 ($22.91) price target on by analysts at UBS. They now have a “buy” rating on the stock.
  • 4/3/2018 – GlaxoSmithKline had its price target raised by analysts at Credit Suisse Group AG from GBX 1,300 ($18.61) to GBX 1,450 ($20.76). They now have a “neutral” rating on the stock.
  • 4/3/2018 – GlaxoSmithKline was given a new GBX 1,400 ($20.05) price target on by analysts at Morgan Stanley. They now have a “neutral” rating on the stock.
  • 3/28/2018 – GlaxoSmithKline was given a new GBX 1,400 ($20.05) price target on by analysts at Morgan Stanley. They now have a “neutral” rating on the stock.
  • 3/28/2018 – GlaxoSmithKline had its price target raised by analysts at Kepler Capital Markets from GBX 1,360 ($19.47) to GBX 1,400 ($20.05). They now have a “hold” rating on the stock.
  • 3/28/2018 – GlaxoSmithKline had its price target raised by analysts at Berenberg Bank from GBX 1,705 ($24.41) to GBX 1,780 ($25.49). They now have a “buy” rating on the stock.
  • 3/28/2018 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 2,030 ($29.07) price target on the stock.
  • 3/27/2018 – GlaxoSmithKline was given a new GBX 1,600 ($22.91) price target on by analysts at UBS. They now have a “buy” rating on the stock.
  • 3/26/2018 – GlaxoSmithKline was given a new GBX 1,650 ($23.63) price target on by analysts at Barclays. They now have a “buy” rating on the stock.
  • 3/23/2018 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at JPMorgan Chase.
  • 3/23/2018 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 3/23/2018 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Deutsche Bank. They now have a GBX 1,440 ($20.62) price target on the stock.
  • 3/23/2018 – GlaxoSmithKline was given a new GBX 1,750 ($25.06) price target on by analysts at Goldman Sachs. They now have a “buy” rating on the stock.
  • 3/22/2018 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at BNP Paribas. They now have a GBX 1,560 ($22.34) price target on the stock.
  • 3/22/2018 – GlaxoSmithKline was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal” rating. They now have a GBX 1,400 ($20.05) price target on the stock, up previously from GBX 1,300 ($18.61).
  • 3/22/2018 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,630 ($23.34) price target on the stock.
  • 3/14/2018 – GlaxoSmithKline had its “sell” rating reaffirmed by analysts at Societe Generale. They now have a GBX 1,130 ($16.18) price target on the stock.
  • 3/8/2018 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,630 ($23.34) price target on the stock.
  • 3/2/2018 – GlaxoSmithKline was given a new GBX 1,750 ($25.06) price target on by analysts at Goldman Sachs. They now have a “buy” rating on the stock.
  • 2/27/2018 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 1,925 ($27.56) price target on the stock.
  • 2/26/2018 – GlaxoSmithKline was given a new GBX 1,475 ($21.12) price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.

GSK opened at GBX 1,404 ($20.10) on Tuesday. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($17.69) and a 52-week high of GBX 1,724.50 ($24.69).

How to Become a New Pot Stock Millionaire

The company also recently announced a dividend, which was paid on Thursday, April 12th. Shareholders of record on Thursday, February 22nd were issued a GBX 23 ($0.33) dividend. This represents a dividend yield of 1.78%. This is a boost from GlaxoSmithKline’s previous dividend of $19.00. The ex-dividend date of this dividend was Thursday, February 22nd.

In other GlaxoSmithKline news, insider Victoria Whyte sold 4,544 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of GBX 1,307 ($18.71), for a total value of £59,390.08 ($85,037.34). Also, insider Sir Roy Anderson bought 562 shares of the stock in a transaction on Wednesday, February 7th. The stock was purchased at an average price of GBX 1,278 ($18.30) per share, with a total value of £7,182.36 ($10,284.02). Over the last quarter, insiders acquired 589 shares of company stock valued at $754,828 and sold 23,765 shares valued at $31,152,709.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.